VCNX

US9186403013

Market Closed - Nasdaq Other stock markets 21:30:00 24/05/2024 BST			5-day change	1st Jan Change
5.4 ^USD	+4.85%		-2.53%	-41.98%

05-16	Earnings Flash (VCNX) VACCINEX Reports Q1 Revenue $104,000	MT
04-12	Vaccinex, Inc. announced that it has received $1.75 million in funding	CI

Vaccinex, Inc. announces Resignation of Raymond E. Watkins as Senior Vice President and Chief Operating Officer

December 09, 2020 at 09:33 pm

Vaccinex, Inc. announced that Raymond E. Watkins departed from his role as the company's Senior Vice President and Chief Operating Officer.

Latest news about VACCINEXPAR

Earnings Flash (VCNX) VACCINEX Reports Q1 Revenue $104,000	05-15	MT
Vaccinex, Inc. announced that it has received $1.75 million in funding	04-11	CI
Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-02	CI
Vaccinex, Inc. announced that it expects to receive $1.75 million in funding	03-28	CI
Vaccinex, Inc. announced that it has received $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C	03-27	CI
Vaccinex, Inc. announced that it expects to receive $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C	03-26	CI
Vaccinex, Inc. announced that it expects to receive $1.49961 million in funding	03-26	CI
Vaccinex, Inc. Announces Chief Financial Officer Changes, Effective March 14, 2024	03-04	CI
Vaccinex, Inc. Announces Executive Changes, Effective March 14, 2024	03-04	CI
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	02-21	MT
Vaccinex Shares Rise as Company Announces Eight New Deals for Antibody Discovery Platform	02-21	MT
Vaccinex, Inc. Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology	02-21	CI
Vaccinex, Inc. announced that it expects to receive $3.700126 million in funding	02-06	CI
Vaccinex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Vaccinex, Inc. Reports Clinical Benefit in Interim Analyses from Two Phase 2 Studies of Pepinemab Combination Treatment At Society for Immunotherapy of Cancer's Annual Meeting	31/10/23	CI
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases	26/10/23	CI
Top Premarket Gainers	06/10/23	MT
Vaccinex Insider Bought Shares Worth $3,000,000, According to a Recent SEC Filing	05/10/23	MT
Vaccinex Insider Bought Shares Worth $509,515, According to a Recent SEC Filing	05/10/23	MT
Top Midday Decliners	29/09/23	MT
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected	29/09/23	MT
Top Premarket Decliners	29/09/23	MT
Vaccinex Prices Offering of Shares, Warrants for Gross Proceeds of About $9.6 Million	29/09/23	MT
Vaccinex's Next Generation ActivMAb®? Technology Published in mAbs	28/09/23	CI
Vaccinex, Inc. to Present Update on PDAC/Pepinemab Study	27/09/23	CI

Vaccinex, Inc. is a clinical-stage biotechnology company. It discovers and develops targeted biotherapeutics to treat diseases with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. Its platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop its lead product candidate pepinemab for the treatment of various diseases and conditions, including cancer and neuroinflammatory and neurodegenerative diseases. Pepinemab's mechanisms of action block the SEMA4D signal and activate innate physiological mechanisms to respond to tumors or tissue injury. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.

Sector

More about the company